Sharekhan

Aarey Drugs and Pharmaceuticals Ltd

Wed 11/06/2025,15:40:4 | NSE : AAREYDRUGS

₹ 53.76-0.82 (-1.50%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 53.05

Previous Close

₹ 54.58

Volume

29216

Mkt Cap ( Rs. Cr)

₹152.43

High

₹ 57.20

Low

₹ 53.05

52 Week High

₹ 74.80

52 Week Low

₹ 31.35

Book Value Per Share

₹ 46.93

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Aarey Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

72.41%

Hold

13.79%

Sell

13.79%

72.41%

29 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Aarey Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Aarey Drugs & Ph - Copy of Newspaper Publication

    3 Jun 2025, 3:41PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
  • Aarey Drugs & Ph - Updates

    3 Jun 2025, 3:40PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding 'Updates'.
  • Aarey Drugs & Ph Q4 net profit down 78.14% at Rs 0.47 cr

    2 Jun 2025, 9:40AM The company reported standalone net profit of Rs 0.47 crore for the quarter ended March 31, 2025 as compared to Rs 2.15 crore in the same period last
  • Aarey Drugs & Ph - Reg. 33 - Audited Financial Results For The Quarter & Financial Year Ended 31St March 2025

    30 May 2025, 10:18PM Audited Financial Result For the year ended on 31st March 2025
  • Aarey Drugs & Ph - Outcome of Board Meeting

    30 May 2025, 10:18PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 30, 2025.
  • Aarey Drugs & Ph - Outcome of Board Meeting

    30 May 2025, 10:11PM Aarey Drugs & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Aarey Drugs & Ph - Board Meeting Outcome for Outcome Of Board Meeting Held On Friday I.E 30Th May, 2025

    30 May 2025, 10:07PM This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 30th May, 2025 have passed the following resolution.\r
  • Aarey Drugs & Ph - Outcome of Board Meeting

    23 May 2025, 2:41PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 23, 2025.
  • Aarey Drugs & Ph - Announcement under Regulation 30 (LODR)-Allotment

    23 May 2025, 2:30PM Allotment of Convertible Warrants pursuant to Preferential Issue.
  • Aarey Drugs & Ph - Board Meeting Intimation

    22 May 2025, 4:49PM AAREY DRUGS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2025 to inter-alia consider and approve the A
  • Aarey Drugs & Ph - Board Meeting Intimation for Board Meeting Intimation

    22 May 2025, 4:57PM Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to
  • Aarey Drugs & Ph - General Updates

    8 May 2025, 2:17PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about General Updates
  • Aarey Drugs & Ph - Reg 30 Of SEBI LODR

    8 May 2025, 2:23PM Reg 30 of SEBI LODR
  • Aarey Drugs & Ph has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    19 Apr 2025, 5:50PM As of March 2025, 44.80% is owned by Indian Promoters and 55.20% by Public. <p align=justify> Top five Promoters holding highest number of shares of A
  • Aarey Drugs & Ph - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 12:53PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2025
  • Aarey Drugs & Ph - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 12:48PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Aarey Drugs & Ph - Clarification On Price Movement

    9 Apr 2025, 4:35PM Clarification on Price Movement
  • Aarey Drugs & Ph - Price movement

    9 Apr 2025, 4:20PM Significant movement in price has been observed in Aarey Drugs & Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest
  • Aarey Drugs & Ph - Price movement

    7 Apr 2025, 5:43PM Significant movement in price has been observed in Aarey Drugs & Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest
  • Aarey Drugs & Ph - Clarification sought from Aarey Drugs & Pharmaceuticals Ltd

    7 Apr 2025, 5:56PM The Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Ltd on April 7, 2025 with reference to significant movement in price, in orde
  • Aarey Drugs & Ph - Trading Window-XBRL

    27 Mar 2025, 2:39PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Closure of Trading Window
  • Aarey Drugs & Ph - Trading Window

    27 Mar 2025, 2:31PM Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)
  • Aarey Drugs board to reconsider stock split

    6 Oct 2017 , 1:25PM Aarey Drugs surges over 14% to Rs87.9, as board to meet on October 12, 2017 to reconsider stock split proposal

Key fundamentals

Evaluate the intrinsic value of Aarey Drugs and Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 173.3364 164.1257 155.1265 127.7997 116.8776
Liabilities 173.3364 164.1257 155.1265 127.7997 116.8776
Equity 28.0543 28.0543 25.3847 25.3846 23.3846
Gross Profit 2.2514 4.4513 7.7213 11.2678 4.6387
Net Profit 4.0239 4.6837 3.7712 6.5447 6.5143
Cash From Operating Activities 9.653 -2.9938 -1.2811 -4.493 5.4769
NPM(%) 0.84 1.18 0.9 1.32 1.86
Revenue 473.9433 395.6179 418.9562 492.6799 348.4164
Expenses 471.6919 391.1666 411.2349 481.4121 343.7776
ROE(%) 3.02 3.51 2.83 4.91 4.89

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Aarey Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 855.40 0.52 28.38 31.06 301.39 0.58
Lotus Eye Hospital and Institute Ltd 72.06 -1.95 205.89 113.19 3.55 0.00
Vaishali Pharma Ltd 12.58 -2.25 209.67 58.34 3.13 0.00
Astec Lifesciences Ltd 808.70 -0.33 0.00 106.73 -687.10 0.00

Company Info

Aarey Drugs & Pharmaceuticals Ltd. (ADPL) was originally incorporated as a private limited company in the name of Niharika Textiles & Chemicals Pvt. Ltd. on 15th May 1990. The Aarey group of companie belonging to the Ghatalia group of companies took over the company and converted it into a public limited company on 18th march 1993. Its name was since changed to Aarey Drugs & Pharmaceuticals Ltd. The main object of the company is to set up facilities for manufacture of bulk drugs. As an immediate step the company has undertaken a project to manufacture Metronidazole and Metronidazole Benzoate at its works situated at E-34, MIDC Estate. 2008 -Aarey Drugs & Pharmaceuticals Ltd has appointed Mr. Chetan Kiritbhai Mehta as an Independent Director of the Company from June 02, 2008. 2012 -Aarey Drugs & Pharmaceuticals Ltd Issues Rights in the Ratio of 2:1 -Aarey Drugs & Pharmaceuticals has given the Bonus in the Ratio of 1:5 2017 -The company has commenced production of new line of product Mefanamic Acid and has confirmed order for the same from its customers up till October, 2017.

Aarey Drugs & Pharmaceuticals Ltd. (ADPL) was originally incorporated as a private limited company in the name of Niharika Textiles & Chemicals Pvt. Ltd. on 15th May 1990. The Aarey group of companie belonging to the Ghatalia group of companies took over the company and converted it into a public limited company on 18th march 1993. Its name was since changed to Aarey Drugs & Pharmaceuticals Ltd. The main object of the company is to set up facilities for manufacture of bulk drugs. As an immediate step the company has undertaken a project to manufacture Metronidazole and Metronidazole Benzoate at its works situated at E-34, MIDC Estate. 2008 -Aarey Drugs & Pharmaceuticals Ltd has appointed Mr. Chetan Kiritbhai Mehta as an Independent Director of the Company from June 02, 2008. 2012 -Aarey Drugs & Pharmaceuticals Ltd Issues Rights in the Ratio of 2:1 -Aarey Drugs & Pharmaceuticals has given the Bonus in the Ratio of 1:5 2017 -The company has commenced production of new line of product Mefanamic Acid and has confirmed order for the same from its customers up till October, 2017.

Read More

Parent Organisation

Aarey Drugs & Pharmaceuticals Ltd.

Founded

15/05/1990

Managing Director

Mr.Mihir R Ghatalia

NSE Symbol

AAREYDRUGSBE

FAQ

The current price of Aarey Drugs and Pharmaceuticals Ltd is ₹ 53.76.

The 52-week high for Aarey Drugs and Pharmaceuticals Ltd is ₹ 57.20 and the 52-week low is ₹ 53.05.

The market capitalization of Aarey Drugs and Pharmaceuticals Ltd is currently ₹ 152.43. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Aarey Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Aarey Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Aarey Drugs and Pharmaceuticals Ltd shares.

The CEO of Aarey Drugs and Pharmaceuticals Ltd is Mr.Mihir R Ghatalia, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT